TY - JOUR
T1 - Allogeneic hematopoietic stem cell transplantation in a prior lung transplant recipient
AU - Fujiwara, Yuki
AU - Matsuoka, Ken ichi
AU - Iwamoto, Miki
AU - Sumii, Yuichi
AU - Abe, Masaya
AU - Mizuhara, Kentaro
AU - Urata, Tomohiro
AU - Saeki, Kyosuke
AU - Meguri, Yusuke
AU - Asada, Noboru
AU - Ennishi, Daisuke
AU - Nishimori, Hisakazu
AU - Fujii, Keiko
AU - Fujii, Nobuharu
AU - Sugita, Junichi
AU - Kobayashi, Hajime
AU - Oto, Takahiro
AU - Maeda, Yoshinobu
N1 - Publisher Copyright:
© 2020, Japanese Society of Hematology.
PY - 2020/12
Y1 - 2020/12
N2 - Hematological diseases after solid organ transplant (SOT) are an emerging issue as the number of long-term SOT survivors increases. Expertise in managing patients requiring allogeneic hematopoietic stem cell transplantation (HSCT) after SOT from independent donors is needed; however, clinical reports of HSCT after SOT are limited, and the feasibility and risk are not well understood. In particular, HSCT in prior lung transplant recipients is thought to be complicated as the lung is immunologically distinct and is constantly exposed to the surrounding environment. Herein, we describe a case of successful HSCT in a patient with myelodysplastic syndromes who had previously received a lung transplant from a deceased donor for bronchiolitis obliterans syndrome. Reports about cases of HSCT after lung transplant are quite rare; thus, we discuss the mechanisms of immune tolerance through the clinical course of our case. This case suggests that HSCT after SOT can be considered a therapeutic option in cases where the transplanted organ is functionally retained and the hematological disease is in remission.
AB - Hematological diseases after solid organ transplant (SOT) are an emerging issue as the number of long-term SOT survivors increases. Expertise in managing patients requiring allogeneic hematopoietic stem cell transplantation (HSCT) after SOT from independent donors is needed; however, clinical reports of HSCT after SOT are limited, and the feasibility and risk are not well understood. In particular, HSCT in prior lung transplant recipients is thought to be complicated as the lung is immunologically distinct and is constantly exposed to the surrounding environment. Herein, we describe a case of successful HSCT in a patient with myelodysplastic syndromes who had previously received a lung transplant from a deceased donor for bronchiolitis obliterans syndrome. Reports about cases of HSCT after lung transplant are quite rare; thus, we discuss the mechanisms of immune tolerance through the clinical course of our case. This case suggests that HSCT after SOT can be considered a therapeutic option in cases where the transplanted organ is functionally retained and the hematological disease is in remission.
KW - Allogeneic hematopoietic stem cell transplantation
KW - Lung transplant
KW - Myelodysplastic syndromes
KW - Transplant tolerance
UR - http://www.scopus.com/inward/record.url?scp=85089554543&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089554543&partnerID=8YFLogxK
U2 - 10.1007/s12185-020-02967-x
DO - 10.1007/s12185-020-02967-x
M3 - Article
C2 - 32803699
AN - SCOPUS:85089554543
SN - 0925-5710
VL - 112
SP - 871
EP - 877
JO - International journal of hematology
JF - International journal of hematology
IS - 6
ER -